Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shiwei Anchang
- Development stage
- Unknown
- Lead developer
- Shanghai University of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
**Shiwei Anchang** (also known as Shiwei Anchang granules) is a Traditional Chinese Medicine (TCM) Class 1.1 innovative drug developed jointly by Kanion Pharmaceutical, Shanghai Tufeng Pharmaceutical Technology, Liaoning Beifeng Pharmaceutical, and the Shanghai University of Traditional Chinese Medicine. Formulated as granules, it is designed for the treatment of ulcerative colitis (UC), specifically targeting the 'spleen deficiency and dampness-accumulation' (脾虚湿蕴) syndrome under TCM theory. Shiwei Anchang exhibits therapeutic effects by strengthening the spleen, clearing the intestines, and stopping diarrhea. In preclinical models of dextran sulfate sodium (DSS)-induced and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis, the drug significantly reduced disease activity, improved mucosal and crypt damage, and alleviated inflammatory infiltration and fibrosis. In October 2026, the National Medical Products Administration (NMPA) of China approved its Investigational New Drug (IND) application to initiate clinical trials for ulcerative colitis.
- Other names
- Shiwei AnchangShiwei Anchang KeliShiwei Anchang granules十味安肠十味安肠颗粒
Beyond the preview
Go deeper on Shiwei Anchang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shiwei Anchang.